Skip to content


    DEA Class;  Rx

    Common Brand Names; Inbrija

    • Antiparkinson Agents, Dopamine Precursors

    Aromatic amine that is metabolized to dopamine
    First-line oral treatment option in combination with carbidopa for motor symptoms in Parkinson’s disease
    Available for oral inhalation for “as needed” use for ‘off’ episodes in Parkinson’s patients receiving levodopa/carbidopa

    Indicated for intermittent treatment of OFF episodes in patients with Parkinson disease treated with carbidopa/levodopa

    Currently or recently (within 2 weeks) taking a nonselective monoamine oxidase (MAO) inhibitor (eg, phenelzine, tranylcypromine)


    Cough (15%)


    Upper respiratory tract infection (6%)

    Discolored sputum (5%)

    Nausea (5%)

    Dyskinesia (4%)

    Fall (3%)

    Vomiting (3%)

    Nasopharyngitis (3%)

    Chest discomfort (2%)

    Increased bilirubin (2%)

    Decreased RBC count (2%)

    Headache (2%)

    Insomnia (2%)

    Orthostatic hypotension/decreased blood pressure (2%)

    Laceration (2%)

    Skin abrasion (2%)

    Bronchitis/pneumonia (2%)

    Discolored nasal discharge (2%)

    Oropharyngeal pain (2%)

    Falling asleep while engaged in activities of daily living, including driving, reported; many patients report somnolence, while other had no warnings signs (sleep attack); some events reported >1 yr after initiating treatment

    Rapid dose reduction, withdrawal of, or changes in dopaminergic therapy may result in a symptom complex that resembles neuroleptic malignant syndrome (eg, elevated temperature, muscular rigidity, altered consciousness, autonomic instability)

    Hallucinations may occur, accompanied by confusion, insomnia, and excessive dreaming; abnormal thinking and behavior may also occur, including, paranoid ideation, delusion, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium

    Decreased impulse control and compulsive behaviors may emerge, including, gambling, sexual urges, spending money, binge eating, and/or other intense urges; patients may not recognize these as abnormal

    May cause or exacerbate dyskinesias

    Owing to bronchospasm risk, not recommended for patients with asthma, COPD, or other chronic lung disease

    May increase intraocular pressure in patients with glaucoma


    There are no available data regarding use in pregnant women


    Levodopa detected in human milk; no data are available on effects in the breastfed infant


    Generally, 8 grams/day PO; 420 mg/day via oral inhalation.


    Generally, 8 grams/day PO; 420 mg/day via oral inhalation.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    capsule, inhalation powder

    • 42mg/capsule
    • Capsule for oral inhalation only and only used with the Inbrija inhaler